Elkins Park, PA, United States of America

James J Mulhearn

This inventor holds 17 USPTO granted patents and 3 published patent applications and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC, Msd R&d (China) Co., Ltd.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James J Mulhearn. Retrieved from https://idiyas.com/inventor/james-j-mulhearn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 94.1

EPO Patents = 11 (Patent Applications = 5)

Average Co-Inventor Count = 8.3

ph-index = 2

Forward Citations = 17(Granted Patents)

Location History:

Saint Davids, PA (US) (2013)
Elkins, PA (US) (2017 - 2021)
North Wales, PA (US) (2021)
Elkins Park, PA (US) (2015 - 2024)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 72

Merck Sharp & Dohme LLC

patents

1 out of 10

Msd R&d (China) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Glucosylceramide Synthase Inhibitors

Voltage-Gated Sodium Channels

HDAC6 Inhibitors

Allosteric Modulators

Phosphonate Linkers

Imaging Agents

Diamino-Aryl Compounds

Benzoxazolinone Compounds

Catechol O-Methyl Transferase

Neurofibrillary Tangles

Modified Isoindolinones

Modified Imidazopyridines

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679807 - Modified isoindolinones as glucosylceramide synthase inhibitors (2026-07-14),

2. 12559491 - Modified imidazopyridines as glucosylceramide synthase inhibitors (2026-02-24),

3. 11970479 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2024-04-30),

4. 11883500 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2024-01-30),

5. 11554172 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2023-01-17),

6. 11066396 - 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors (2021-07-20),

7. 10968210 - Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2021-04-06),

8. 10869929 - Phosphonate linkers and their use to facilitate cellular retention of compounds (2020-12-22),

9. 10519147 - Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2019-12-31),

10. 10221167 - Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2019-03-05),

11. 10022461 - Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles (2018-07-17),

12. 9808542 - Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrillary (2017-11-07),

13. 9624208 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels (2017-04-18),

14. 9399651 - Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders (2016-07-26),

15. 9273040 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels (2016-03-01),

Title: The Innovations of James J Mulhearn: Pioneer in Neurological and Psychiatric Treatments

Introduction: James J Mulhearn, an accomplished inventor based in Elkins Park, PA, is recognized for his significant contributions to the field of neuroscience. With a remarkable portfolio of 15 patents, Mulhearn has been at the forefront of developing innovative compounds aimed at treating various neurological and psychiatric disorders.

Latest Patents: Among his notable inventions, the most recent patents include a groundbreaking compound known as 3-(1H-pyrazol-4-yl)pyridine, characterized as an allosteric modulator of the M4 muscarinic acetylcholine receptor. This invention holds promise for therapeutic applications in the treatment and prevention of disorders linked with M4 muscarinic acetylcholine receptors. Additionally, he has developed phosphonate linkers that enhance cellular retention of compounds, facilitating the delivery of therapeutics with passive cell permeability into target cells.

Career Highlights: Mulhearn's career has seen him collaborate with prestigious organizations, most notably Merck Sharp & Dohme Corporation. His work in pharmaceutical research has contributed to advancements in drug development, particularly in creating innovative solutions for complex health challenges.

Collaborations: Throughout his illustrious career, Mulhearn has worked alongside notable colleagues such as Thomas J Greshock and Scott E Wolkenberg. Their combined expertise reflects a commitment to pushing the boundaries of scientific innovation, particularly in the realms of neuroscience and pharmacology.

Conclusion: James J Mulhearn's contributions to the field of medical science exemplify the spirit of innovation in addressing critical health issues. His inventions not only signify advancements in pharmaceutical research but also open new avenues for the treatment of neurological and psychiatric disorders. As he continues to explore the potential of his inventions, the impact of his work is sure to resonate within the scientific community and beyond.

Profile summary based on public USPTO records.